Tier 2 — strong

Quercetin intervention reduced hepatic fat deposition in patients with nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled crossover clinical trial

NingChao Li, Chun Cui, Jing Xu, ManTian Mi, Jian Wang, Yu Qin
The American journal of clinical nutrition 2024 120(3):507-517

Bibliography

PubMed
PMID 39032786
DOI
10.1016/j.ajcnut.2024.07.013
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled crossover trial
ModelHuman intervention research
Sample41 randomized adults with fatty liver; 36 completed
InterventionQuercetin 500 mg/day versus placebo
Duration12 weeks per treatment, separated by 4-week washout
EndpointsLiver measurements

What the study showed, in plain terms

Published in 2024, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled crossover trial. Sample/model: 41 randomized adults with fatty liver; 36 completed. The exposure or intervention was Quercetin 500 mg/day versus placebo. Follow-up or treatment period: 12 weeks per treatment, separated by 4-week washout.

Liver fat fell more with quercetin, alongside modest weight loss. Other secondary and safety outcomes did not differ significantly.

Small crossover trial. Weight loss may help explain the liver-fat change; fibrosis improvement and long-term liver outcomes were not established.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Liver fat fell more with quercetin, alongside modest weight loss.
  • Other secondary and safety outcomes did not differ significantly.
  • The recorded outcome domains were Liver measurements.
  • The result applies to the tested exposure: Quercetin 500 mg/day versus placebo; 12 weeks per treatment, separated by 4-week washout.

What this study can and cannot tell us

  • Small crossover trial. Weight loss may help explain the liver-fat change; fibrosis improvement and long-term liver outcomes were not established.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology